Quarterly report pursuant to Section 13 or 15(d)

Collaboration And Licensing Agreements (Details Narrative)

v3.7.0.1
Collaboration And Licensing Agreements (Details Narrative) - USD ($)
9 Months Ended
Feb. 03, 2016
Jul. 31, 2017
Feb. 27, 2017
Oct. 31, 2016
Other receivable   $ 1,500,000  
Received payments from related parties   3,000,000    
Sellas Life Science Group [Member]        
Received payments from related parties     $ 358,000,000  
Amgen Agreement [Member]        
Payment to acquire research and development   4,500,000    
Amgen Agreement [Member] | August 2017 [Member]        
Payment to acquire research and development   $ 1,500,000    
Stendhal Agreement [Member]        
Support payment expenses $ 10,000,000      
Support payment expense description Certain internal expenses of Stendhal up to $1 million shall be counted towards the $10 million in Support Payments.      
Maximum internal expense $ 1,000,000